We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com. Community Guidelines: bit.ly/2MgAcio Pharmaceutical, Biopharmaceutical, Innovation, Research and development, and Global business

Sectors: Pharmaceutical

Transforming Tomorrow Together UK Research and Innovation (UKRI) is the public sector organisation that invests £8 billion annually to support the entire research and innovation system. We strive for a society powered and empowered by research and innovation, with economic, social, environmental and cultural benefits for all. We invest in people, places, ideas, innovation and impacts, empowering researchers, innovators and entrepreneurs to turn the many challenges we all face into opportunities, driving up prosperity and wellbeing across the UK and globally. The impacts of our work are felt right across society. We enrich lives by increasing our understanding of ourselves …

Sectors: Public business cluster

About the Financial Times The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community. Learn more about the FT, including announcements and career opportunities, at aboutus.ft.com. Subscribe at subs.ft.com. One of the world’s leading business news organisations

Sectors: Media

Visionary ventures IP Group accelerates the impact of science for a better future. As the most active UK based, early-stage science investor, we develop and support some of the world’s most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxbotica. IP …